159 related articles for article (PubMed ID: 34629258)
21. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus.
Mantovani A; Morieri ML; Palmisano L; Masulli M; Cossu E; Baroni MG; Bonomo K; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Aldigeri R; Cas AD; de Kreutzenberg SV; Targher G
Cardiovasc Diabetol; 2023 Aug; 22(1):204. PubMed ID: 37563618
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
23. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
[TBL] [Abstract][Full Text] [Related]
24. Effect of Policaptil Gel Retard on Liver Fat Content and Fibrosis in Adults with Metabolic Syndrome and Type 2 Diabetes: A Non-invasive Approach to MAFLD.
Guarino G; Strollo F; Della Corte T; Satta E; Gentile S
Diabetes Ther; 2023 Dec; 14(12):2089-2108. PubMed ID: 37789214
[TBL] [Abstract][Full Text] [Related]
25. Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study.
Arslan AY; Celik S; Amin F; Caylak I; Kesapli I; Kilic IB; Karakullukcu S; Ardic C; Yilmaz Y
Hepatol Forum; 2024; 5(2):63-67. PubMed ID: 38487737
[TBL] [Abstract][Full Text] [Related]
26. Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease.
Namakchian M; Rabizadeh S; Seifouri S; Asadigandomani H; Bafrani MA; Seifouri K; Avanaki FA; Rajab A; Nakhjavani M; Esteghamati A
Diabetol Metab Syndr; 2023 Mar; 15(1):57. PubMed ID: 36964605
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
28. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
29. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
30. GLP-1 receptor agonists in NAFLD.
Petit JM; Vergès B
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
[TBL] [Abstract][Full Text] [Related]
31. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
[TBL] [Abstract][Full Text] [Related]
33. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
Lu JM
Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
[TBL] [Abstract][Full Text] [Related]
34. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.
Fan H; Li L; Liu Z; Zhang P; Wu S; Han X; Chen X; Suo C; Cao L; Zhang T
BMC Gastroenterol; 2023 Jan; 23(1):3. PubMed ID: 36604612
[TBL] [Abstract][Full Text] [Related]
35. Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.
Bonora BM; Rigato M; Frison V; D'Ambrosio M; Tadiotto F; Lapolla A; Simioni N; Paccagnella A; Avogaro A; Fadini GP
Diabetes Res Clin Pract; 2021 Mar; 173():108686. PubMed ID: 33548335
[TBL] [Abstract][Full Text] [Related]
36. Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity.
Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sánchez FJ; Gómez Huelgas R; Casas Rojo JM; Suárez Tembra M; Carabantes Rueda JJ; Arévalo Lorido JC
Curr Med Res Opin; 2021 Nov; 37(11):1867-1873. PubMed ID: 34357836
[TBL] [Abstract][Full Text] [Related]
37. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
38. Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases.
Mostafa AM; Hafez SM; Abdullah NM; Fouad Y
Eur J Gastroenterol Hepatol; 2024 May; 36(5):665-673. PubMed ID: 38477854
[TBL] [Abstract][Full Text] [Related]
39. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
Busch RS; Kane MP
Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
[TBL] [Abstract][Full Text] [Related]
40. Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD.
Jirapinyo P; Jaroenlapnopparat A; Zucker SD; Thompson CC
Obes Surg; 2024 May; 34(5):1471-1478. PubMed ID: 38512644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
